bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary figure S4 from Multimodal CEA-Targeted Image-Guided Colorectal Cancer Surgery using 111In-Labeled SGM-101
Authors: de Gooyer Jan Marie , Elekonawo Fortuné M.K. , Bos Desirée L. , van der Post Rachel S. , Pèlegrin André , Framery Bérénice , Cailler Françoise , Vahrmeijer Alexander L. , de Wilt Johannes H.W. , Rijpkema Mark
Published: April 2023

Supplemental figure 4 shows slide 3 of figure 4 at a higher magnification (5x). Clear colocalization of CEA-expressing tumor cells can be observed. From left to right: H&E staining, CEA immunohistochemistry, NIR Fluorescence.
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Authors: Byrd John C. , Furman Richard R. , Coutre Steven E. , Flinn Ian W. , Burger Jan A. , Blum Kristie , Sharman Jeff P. , Wierda William , Zhao Weiqiang , Heerema Nyla A. , Luan Ying , Liu Emily A. , Dean James P. , O'Brien Susan
Published: April 2023

Supplementary Table S1: Patient disposition and dose modification in patients receiving ibrutinib in the first-line and relapsed/refractory treatment settings
Supplementary Movie S1 from TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions
Authors: Cohen Allison S. , Li Jun , Hight Matthew R. , McKinley Eliot , Fu Allie , Payne Adria , Liu Yang , Zhang Dawei , Xie Qing , Bai Mingfeng , Ayers Gregory D. , Tantawy Mohammed Noor , Smith Jarrod A. , Revetta Frank , Washington M. Kay , Shi Chanjuan , Merchant Nipun , Manning H. Charles
Published: April 2023

Real-time image-guided surgery of littermate control mouse using V-1520
Supplementary Figure S4 from TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions
Authors: Cohen Allison S. , Li Jun , Hight Matthew R. , McKinley Eliot , Fu Allie , Payne Adria , Liu Yang , Zhang Dawei , Xie Qing , Bai Mingfeng , Ayers Gregory D. , Tantawy Mohammed Noor , Smith Jarrod A. , Revetta Frank , Washington M. Kay , Shi Chanjuan , Merchant Nipun , Manning H. Charles
Published: April 2023

Comparison of optical imaging with V-1520 and IRDye800CW
Figure S7 from CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma
Authors: Cannon Andrew , Thompson Christopher M. , Maurer H. Carlo , Atri Pranita , Bhatia Rakesh , West Sean , Ghersi Dario , Olive Kenneth P. , Kumar Sushil , Batra Surinder K.
Published: April 2023

CIBERSORT analysis of micrarray data by CXCR3 and its ligands expression.
Figure S6 from CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma
Authors: Cannon Andrew , Thompson Christopher M. , Maurer H. Carlo , Atri Pranita , Bhatia Rakesh , West Sean , Ghersi Dario , Olive Kenneth P. , Kumar Sushil , Batra Surinder K.
Published: April 2023

GSEA of TCGA data by CXCR3 and its ligands.
Figure S5 from CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma
Authors: Cannon Andrew , Thompson Christopher M. , Maurer H. Carlo , Atri Pranita , Bhatia Rakesh , West Sean , Ghersi Dario , Olive Kenneth P. , Kumar Sushil , Batra Surinder K.
Published: April 2023

Survival by PF4 expression in TCGA top 25% compared to bottom 75%.
Supplementary Appendix from Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275
Authors: Galsky Matthew D. , Saci Abdel , Szabo Peter M. , Han G. Celine , Grossfeld Gary , Collette Sandra , Siefker-Radtke Arlene , Necchi Andrea , Sharma Padmanee
Published: April 2023

This appendix includes all supplemental tables and figures referenced in the article.
Supplementary Data from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma
Authors: Casey Dana L. , Wexler Leonard H. , Pitter Kenneth L. , Samstein Robert M. , Slotkin Emily K. , Wolden Suzanne L.
Published: April 2023

Supplementary Figure Legends
Supplementary Table 1 from Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer
Authors: Perkons Nicholas R. , Johnson Omar , Pilla Gabrielle , Profka Enri , Mercadante Michael , Ackerman Daniel , Gade Terence P.F.
Published: April 2023

This table, organized by cancer type, includes: (1) the top five differentially essential genes in each cancer type, (2) imaging-associated differentially essential genes (where p<0.0005), (3) DNP-MRS probes associated with imaging genes identified in (2) as described by Supplementary Tables 2 and 3, and (4) novel potential protein-probe pairs among genes listed in (1) when no imaging associated genes were identified in (3). Differentially essential genes were identified based on two criteria: (1) the mean CERES score for the cancer type must be < 0 and (2) the mean CERES score must be statistically less than that of all other cancer types studies (p<0.0005). *: HCC is a subset of liver cancers.
Supplementary Figure S7 from Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells
Authors: Ichikawa Junya , Yoshida Tatsuya , Isser Ariel , Laino Andressa S. , Vassallo Melinda , Woods David , Kim Sojung , Oelke Mathias , Jones Kristi , Schneck Jonathan P. , Weber Jeffrey S.
Published: April 2023

Functional analysis of nano-aAPC expanded MART-1 Tet+ CD8+ T-cells post-PD-1 treatment.
Supplementary Table IV from Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts
Authors: Mehta Ranjit K. , Pal Sanjima , Kondapi Koushik , Sitto Merna , Dewar Cuyler , Devasia Theresa , Schipper Matthew J. , Thomas Dafydd G. , Basrur Venkatesha , Pai Manjunath P. , Morishima Yoshihiro , Osawa Yoichi , Pratt William B. , Lawrence Theodore S. , Nyati Mukesh K.
Published: April 2023

Functional Annotation Chart for significantly down regulated proteins
Supplementary Figure SF3 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Radiological necrosis in a thalamic Grade III tumor
Supplementary Figure SF10 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Survival curves of Event Free Survival (EFS) and Overall Survival (OS) of H3 F3A_K27 mutant vs other midline tumours
Supplementary Figure SF1 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Tumor grade vs imaging characteristics
Supplementary Materials and Methods from Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma
Authors: Mendez Flor , Kadiyala Padma , Nunez Felipe J. , Carney Stephen , Nunez Fernando M. , Gauss Jessica C. , Ravindran Ramya , Pawar Sheeba , Edwards Marta , Garcia-Fabiani Maria Belen , Haase Santiago , Lowenstein Pedro R. , Castro Maria G.
Published: April 2023

Summplementary Materials and Methods
Figure S4 from Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma
Authors: Mendez Flor , Kadiyala Padma , Nunez Felipe J. , Carney Stephen , Nunez Fernando M. , Gauss Jessica C. , Ravindran Ramya , Pawar Sheeba , Edwards Marta , Garcia-Fabiani Maria Belen , Haase Santiago , Lowenstein Pedro R. , Castro Maria G.
Published: April 2023

Characterization of intracranial implantation model
Figure S7 from Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia
Authors: Laurent Anouchka P. , Siret Aurélie , Ignacimouttou Cathy , Panchal Kunjal , Diop M'Boyba , Jenni Silvia , Tsai Yi-Chien , Roos-Weil Damien , Aid Zakia , Prade Nais , Lagarde Stephanie , Plassard Damien , Pierron Gaelle , Daudigeos Estelle , Lecluse Yann , Droin Nathalie , Bornhauser Beat C. , Cheung Laurence C. , Crispino John D. , Gaudry Muriel , Bernard Olivier A. , Macintyre Elizabeth , Barin Bonnigal Carole , Kotecha Rishi S. , Geoerger Birgit , Ballerini Paola , Bourquin Jean-Pierre , Delabesse Eric , Mercher Thomas , Malinge Sebastien
Published: April 2023

Efficacy of conventional chemotherapeutic agents alone or in combination with Trametinib in PDX B-ALL cells in vitro
Supplementary Data from Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells
Authors: Aboulnasr Fatma , Krogman Ashton , Graham Rondell P. , Cummins Nathan W. , Misra Anisha , Garcia-Rivera Enrique , Anderson Jeff R. , Natesampillai Sekar , Kogan Nicole , Aravamudan Murali , Nie Zilin , Chung Thomas D.Y. , Buick Richard , Feldman Andrew L. , King Rebecca L. , Novak Anne J. , Ansell Stephen M. , Kenderian Saad , Badley Andrew D.
Published: April 2023

Supplementary tables and figures
eTable 4 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials
Authors: Stahler Arndt , Stintzing Sebastian , Modest Dominik P. , Ricard Ingrid , Giessen-Jung Clemens , Kapaun Christine , Ivanova Boryana , Kaiser Florian , Fischer von Weikersthal Ludwig , Moosmann Nicolas , Schalhorn Andreas , Stauch Martina , Kiani Alexander , Held Swantje , Decker Thomas , Moehler Markus , Neumann Jens , Kirchner Thomas , Jung Andreas , Heinemann Volker
Published: April 2023

Outcome of high vs. low normalized AREG expression according to molecular tumor characteristics by univariate Cox regression for overall and progression-free survival.
Supplementary Figure 3 from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer
Authors: Krop Ian , Abramson Vandana , Colleoni Marco , Traina Tiffany , Holmes Frankie , Garcia-Estevez Laura , Hart Lowell , Awada Ahmad , Zamagni Claudio , Morris Patrick G. , Schwartzberg Lee , Chan Stephen , Gucalp Ayca , Biganzoli Laura , Steinberg Joyce , Sica Lorenzo , Trudeau Maureen , Markova Denka , Tarazi Jamal , Zhu Zhou , O'Brien Thomas , Kelly Catherine M. , Winer Eric , Yardley Denise A.
Published: April 2023

Plasma trough concentrations by week for (A) enzalutamide and (B) exemestane The labeled values denote mean (SD). The open circles denote trough concentration values of individual patients. Solid squares and vertical lines denote mean with error bars by one SD in both directions. Abbreviations: SD, standard deviation.
eTable 2 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials
Authors: Stahler Arndt , Stintzing Sebastian , Modest Dominik P. , Ricard Ingrid , Giessen-Jung Clemens , Kapaun Christine , Ivanova Boryana , Kaiser Florian , Fischer von Weikersthal Ludwig , Moosmann Nicolas , Schalhorn Andreas , Stauch Martina , Kiani Alexander , Held Swantje , Decker Thomas , Moehler Markus , Neumann Jens , Kirchner Thomas , Jung Andreas , Heinemann Volker
Published: April 2023

Univariate and multivariate Cox regression analyses for overall and progression-free survival in all patients.
eFigure 4 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials
Authors: Stahler Arndt , Stintzing Sebastian , Modest Dominik P. , Ricard Ingrid , Giessen-Jung Clemens , Kapaun Christine , Ivanova Boryana , Kaiser Florian , Fischer von Weikersthal Ludwig , Moosmann Nicolas , Schalhorn Andreas , Stauch Martina , Kiani Alexander , Held Swantje , Decker Thomas , Moehler Markus , Neumann Jens , Kirchner Thomas , Jung Andreas , Heinemann Volker
Published: April 2023

Forest plot of individual trial analysis of high versus low amphiregulin (AREG) mRNA expression dichotomized by median and 3rd quartile showing (A) hazard ratios (HR) and 95% confidence interval (95% CI) for overall survival and (B) hazard ratios (HR) and 95% confidence interval (95% CI) for progression-free survival
eFigure 3 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials
Authors: Stahler Arndt , Stintzing Sebastian , Modest Dominik P. , Ricard Ingrid , Giessen-Jung Clemens , Kapaun Christine , Ivanova Boryana , Kaiser Florian , Fischer von Weikersthal Ludwig , Moosmann Nicolas , Schalhorn Andreas , Stauch Martina , Kiani Alexander , Held Swantje , Decker Thomas , Moehler Markus , Neumann Jens , Kirchner Thomas , Jung Andreas , Heinemann Volker
Published: April 2023

Median AREG (A) and EGFR (B) expression and their 95% confidence interval (95% CI, grey shaded). Median AREG expression was lower in right- compared to left-sided primary tumor locations, while only tumors located in caecum, ascending colon, hepatic flexure and descending colon showed low EGFR expression. The red dashed lines mark the pre-specified threshold values 0.5 for AREG and 22.5 for EGFR expression.
Supplementary Figure 4 from ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Authors: Turner Nicholas C. , Swift Claire , Kilburn Lucy , Fribbens Charlotte , Beaney Matthew , Garcia-Murillas Isaac , Budzar Aman U. , Robertson John F.R. , Gradishar William , Piccart Martine , Schiavon Gaia , Bliss Judith M. , Dowsett Mitch , Johnston Stephen R.D. , Chia Stephen K.
Published: April 2023

Supplementary Figure 4. Individual ESR1 mutation detection and polyclonality in SoFEA and in EFECT
Supplementary Figure 2 from ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Authors: Turner Nicholas C. , Swift Claire , Kilburn Lucy , Fribbens Charlotte , Beaney Matthew , Garcia-Murillas Isaac , Budzar Aman U. , Robertson John F.R. , Gradishar William , Piccart Martine , Schiavon Gaia , Bliss Judith M. , Dowsett Mitch , Johnston Stephen R.D. , Chia Stephen K.
Published: April 2023

Supplementary Figure 2. Consort diagram of patients analysed from EFECT
Supplementary Data from Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma
Authors: Ubels Joske , Sonneveld Pieter , van Vliet Martin H. , de Ridder Jeroen
Published: April 2023

All supplementary tables and figures mentioned in the manuscript
Supplementary Figure 1 from ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Authors: Turner Nicholas C. , Swift Claire , Kilburn Lucy , Fribbens Charlotte , Beaney Matthew , Garcia-Murillas Isaac , Budzar Aman U. , Robertson John F.R. , Gradishar William , Piccart Martine , Schiavon Gaia , Bliss Judith M. , Dowsett Mitch , Johnston Stephen R.D. , Chia Stephen K.
Published: April 2023

Supplementary Figure 1. Impact of DNA input amount on ESR1 mutation detection in EFECT
Fold Assignment from Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma
Authors: Ubels Joske , Sonneveld Pieter , van Vliet Martin H. , de Ridder Jeroen
Published: April 2023

An excel file detailing which patients were assigned to which fold during the training procedure to ensure reproducibility
Figure S4 from Genomic Profiling of Prostate Cancers from Men with African and European Ancestry
Authors: Koga Yusuke , Song Hanbing , Chalmers Zachary R. , Newberg Justin , Kim Eejung , Carrot-Zhang Jian , Piou Daphnee , Polak Paz , Abdulkadir Sarki A. , Ziv Elad , Meyerson Matthew , Frampton Garrett M. , Campbell Joshua D. , Huang Franklin W.
Published: April 2023

Comparison of alteration frequencies between localized and metastatic PCa. Comparison of alteration frequencies for each gene between localized and metastatic PCa samples in both AFR (localized: N = 251, metastatic: N = 185, lower panel) and EUR groups (localized: N = 1940, metastatic: N = 1078, upper panel). Solid black lines represent a 1:1 relationship between localized and metastatic PCa patients. Open grey circles are genes with no significant differences (FDR >= 0.05) and solid purple circles are genes with significantly different alteration rates (FDR < 0.05). Gene names are labeled beside their corresponding markers in the scatter plots.
Figure S3 from Genomic Profiling of Prostate Cancers from Men with African and European Ancestry
Authors: Koga Yusuke , Song Hanbing , Chalmers Zachary R. , Newberg Justin , Kim Eejung , Carrot-Zhang Jian , Piou Daphnee , Polak Paz , Abdulkadir Sarki A. , Ziv Elad , Meyerson Matthew , Frampton Garrett M. , Campbell Joshua D. , Huang Franklin W.
Published: April 2023

Combined analysis of mutations and deletions. Genes with both available mutational data and copy number data were associated with race while controlling for Gleason score and age using logistic regression. A purple dot indicates a significant association with race (FDR < 0.05).
Supplementary Figure S7 from Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling
Authors: Zugazagoitia Jon , Gupta Swati , Liu Yuting , Fuhrman Kit , Gettinger Scott , Herbst Roy S. , Schalper Kurt A. , Rimm David L.
Published: April 2023

Absolute CD56+/CK- cell count distribution in the tumor compartment (A), the stromal compartment (B), and the entire TMA core (C); Percentage of CD56+/CK- cells in the stroma according to CB groups (D); Absolute CD56+/CK- cell counts according to clinical benefit groups (E)
Supplementary Figure S4 from Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling
Authors: Zugazagoitia Jon , Gupta Swati , Liu Yuting , Fuhrman Kit , Gettinger Scott , Herbst Roy S. , Schalper Kurt A. , Rimm David L.
Published: April 2023

Correlation between STING expression in the tumor compartment (A) and HLA-DR expression in the tumor compartment (B) in YTMA404 block 1 and YTMA404 block 2; and correlation between CD3 expression in the CD45 compartment (C) and PD-L1 expression in the tumor compartment (D) YTMA404 block 1 and YTMA404 block 2 (B)
Supplementary Data from Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia
Authors: Thangavadivel Shanmugapriya , Zhao Qiuhong , Epperla Narendranath , Rike Lindsey , Mo Xiaokui , Badawi Mohamed , Bystry Darlene M. , Phelps Mitch A. , Andritsos Leslie A. , Rogers Kerry A. , Jones Jeffrey , Woyach Jennifer A. , Byrd John C. , Awan Farrukh T.
Published: April 2023

Supplementary file
Methods and Tables S1-S3 from Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
Authors: Goyal Lipika , Sirard Cynthia , Schrag Michael , Kagey Michael H. , Eads Jennifer R. , Stein Stacey , El-Khoueiry Anthony B. , Manji Gulam A. , Abrams Thomas A. , Khorana Alok A. , Miksad Rebecca , Mahalingam Devalingam , Zhu Andrew X. , Duda Dan G.
Published: April 2023

Text and Tables
Tables S2-1 and S2-2 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Authors: Tang Bixia , Chi Zhihong , Chen Yingbo , Liu Xiufeng , Wu Di , Chen Jing , Song Xin , Wang Weifeng , Dong Lihou , Song Haifeng , Wu Hai , Feng Hui , Yao Sheng , Qin Shuikui , Zhang Xiaoshi , Guo Jun
Published: April 2023

Clinical efficacy and survival evaluated by independent review committee (IRC) and investigator per RECIST v1.1 in melanoma subgroups. And Top 20% TMB value in each subtype as cut-off for efficacy analysis.
Table S5 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Authors: Tang Bixia , Chi Zhihong , Chen Yingbo , Liu Xiufeng , Wu Di , Chen Jing , Song Xin , Wang Weifeng , Dong Lihou , Song Haifeng , Wu Hai , Feng Hui , Yao Sheng , Qin Shuikui , Zhang Xiaoshi , Guo Jun
Published: April 2023

Sequencing Sample Listings
Supplementary Table 3 from STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
Authors: Proia Theresa A. , Singh Maneesh , Woessner Richard , Carnevalli Larissa , Bommakanti Gayathri , Magiera Lukasz , Srinivasan Srimathi , Grosskurth Shaun , Collins Mike , Womack Chris , Griffin Matthew , Ye Minwei , Cantin Susan , Russell Deanna , Xie Mingchao , Hughes Adina , Deng Nanhua , Mele Deanna A. , Fawell Stephen , Barry Simon , Reimer Corinne , Barrett J. Carl , McCoon Patricia
Published: April 2023

Gene expression signatures used in Figure 1
Supplementary Table 2 from STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
Authors: Proia Theresa A. , Singh Maneesh , Woessner Richard , Carnevalli Larissa , Bommakanti Gayathri , Magiera Lukasz , Srinivasan Srimathi , Grosskurth Shaun , Collins Mike , Womack Chris , Griffin Matthew , Ye Minwei , Cantin Susan , Russell Deanna , Xie Mingchao , Hughes Adina , Deng Nanhua , Mele Deanna A. , Fawell Stephen , Barry Simon , Reimer Corinne , Barrett J. Carl , McCoon Patricia
Published: April 2023

Patient tumor gene expression data
Table S1 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Authors: Tang Bixia , Chi Zhihong , Chen Yingbo , Liu Xiufeng , Wu Di , Chen Jing , Song Xin , Wang Weifeng , Dong Lihou , Song Haifeng , Wu Hai , Feng Hui , Yao Sheng , Qin Shuikui , Zhang Xiaoshi , Guo Jun
Published: April 2023

Grade 3 and above treatment-related adverse events in the study.
Figure S3 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Authors: Tang Bixia , Chi Zhihong , Chen Yingbo , Liu Xiufeng , Wu Di , Chen Jing , Song Xin , Wang Weifeng , Dong Lihou , Song Haifeng , Wu Hai , Feng Hui , Yao Sheng , Qin Shuikui , Zhang Xiaoshi , Guo Jun
Published: April 2023

The correlation of clinical response with IFN-ï�§ related, inflammation or angiogenesis signature panel scores. IFN-gammaï�§ related panel: IDO1, CXCL10, CXCL9, HLA-DRA, STAT1, and IFNG; angiogenesis signature panel: VEGFA, KDR, ESM1, PECAM1, ANGPTL4, and CD34; inflammation panel: IL-6, CXCL1, CXCL2, CXCL3, CXCL8, and PTGS2. Responders: complete or partial response or stable disease; Nonresponders: progressive disease.
Supplementary Figures 8 and 9 from STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
Authors: Proia Theresa A. , Singh Maneesh , Woessner Richard , Carnevalli Larissa , Bommakanti Gayathri , Magiera Lukasz , Srinivasan Srimathi , Grosskurth Shaun , Collins Mike , Womack Chris , Griffin Matthew , Ye Minwei , Cantin Susan , Russell Deanna , Xie Mingchao , Hughes Adina , Deng Nanhua , Mele Deanna A. , Fawell Stephen , Barry Simon , Reimer Corinne , Barrett J. Carl , McCoon Patricia
Published: April 2023

Effects on cultured (human and mouse) immune cells
Figure S1 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Authors: Tang Bixia , Chi Zhihong , Chen Yingbo , Liu Xiufeng , Wu Di , Chen Jing , Song Xin , Wang Weifeng , Dong Lihou , Song Haifeng , Wu Hai , Feng Hui , Yao Sheng , Qin Shuikui , Zhang Xiaoshi , Guo Jun
Published: April 2023

CONSORT diagram for the Phase II study of toripalimab treating patients with locally advanced or metastatic melanoma refractory to systemic therapy.
Supplementary Figures 1 and 2 from STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
Authors: Proia Theresa A. , Singh Maneesh , Woessner Richard , Carnevalli Larissa , Bommakanti Gayathri , Magiera Lukasz , Srinivasan Srimathi , Grosskurth Shaun , Collins Mike , Womack Chris , Griffin Matthew , Ye Minwei , Cantin Susan , Russell Deanna , Xie Mingchao , Hughes Adina , Deng Nanhua , Mele Deanna A. , Fawell Stephen , Barry Simon , Reimer Corinne , Barrett J. Carl , McCoon Patricia
Published: April 2023

Patient STAT reductions and reproducibility of replicates
Supplementary TABLE 3 from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Authors: Merz Valeria , Zecchetto Camilla , Santoro Raffaela , Simionato Francesca , Sabbadini Fabio , Mangiameli Domenico , Piro Geny , Cavaliere Alessandro , Deiana Michela , Valenti Maria Teresa , Bazan Diana , Fedele Vita , Lonardi Sara , Melisi Davide
Published: April 2023

Supplementary TABLE 3
Supplementary TABLE 2 from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Authors: Merz Valeria , Zecchetto Camilla , Santoro Raffaela , Simionato Francesca , Sabbadini Fabio , Mangiameli Domenico , Piro Geny , Cavaliere Alessandro , Deiana Michela , Valenti Maria Teresa , Bazan Diana , Fedele Vita , Lonardi Sara , Melisi Davide
Published: April 2023

Supplementary TABLE 2
Supplementary Table S3 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Authors: Carrato Cristina , Alameda Francesc , Esteve-Codina Anna , Pineda Estela , Arpí Oriol , Martinez-García Maria , Mallo Mar , Gut Marta , Lopez-Martos Raquel , Barco Sonia Del , Ribalta Teresa , Capellades Jaume , Puig Josep , Gallego Oscar , Mesia Carlos , Muñoz-Marmol Ana M , Archilla Ivan , Arumí Montserrat , Blanc Julie Marie , Bellosillo Beatriz , Menendez Silvia , Esteve Anna , Bagué Silvia , Hernandez Ainhoa , Craven-Bartle Jordi , Fuentes Rafael , Vidal Noemí , Aldecoa Iban , Iglesia Nuria de la , Balana Carmen
Published: April 2023

Patient characteristics and molecular subtypes
Supplementary Fig. S4 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Authors: Carrato Cristina , Alameda Francesc , Esteve-Codina Anna , Pineda Estela , Arpí Oriol , Martinez-García Maria , Mallo Mar , Gut Marta , Lopez-Martos Raquel , Barco Sonia Del , Ribalta Teresa , Capellades Jaume , Puig Josep , Gallego Oscar , Mesia Carlos , Muñoz-Marmol Ana M , Archilla Ivan , Arumí Montserrat , Blanc Julie Marie , Bellosillo Beatriz , Menendez Silvia , Esteve Anna , Bagué Silvia , Hernandez Ainhoa , Craven-Bartle Jordi , Fuentes Rafael , Vidal Noemí , Aldecoa Iban , Iglesia Nuria de la , Balana Carmen
Published: April 2023

Representative images comparing high versus low immunohistochemical expression of (A,B) EGFR,(C,D) PTEN, (E,F) SOX-2, (G,H) SHC1, (I,J) TCIRG1,(K,L) IDH1R132H (K:positive, L: negative), (M,N) Olig2,and (O,P) Ki67
Figure S13. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Authors: Merz Valeria , Zecchetto Camilla , Santoro Raffaela , Simionato Francesca , Sabbadini Fabio , Mangiameli Domenico , Piro Geny , Cavaliere Alessandro , Deiana Michela , Valenti Maria Teresa , Bazan Diana , Fedele Vita , Lonardi Sara , Melisi Davide
Published: April 2023

The hazard ratios (HRs) with 95% CI are shown in dependence of possible cutoff points of IL-8 for median progression-free survival (mPFS) (A) and overall survival (OS) (D) duration of patients in the validation cohort. The differences in mean survival times are estimated for each IL-8 value for mPFS (B) and mOS (E). The histogram shows the relative frequency of each IL-8 value for mPFS (C) and mOS (F). The optimal cutoff is marked by a vertical line.
Figure S11. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Authors: Merz Valeria , Zecchetto Camilla , Santoro Raffaela , Simionato Francesca , Sabbadini Fabio , Mangiameli Domenico , Piro Geny , Cavaliere Alessandro , Deiana Michela , Valenti Maria Teresa , Bazan Diana , Fedele Vita , Lonardi Sara , Melisi Davide
Published: April 2023

The histograms report the relative frequency for each cytokine value and the distribution of values compared to the cut-off calculated for overall survival of patients in the discovery cohort. The histograms are referred to eotaxin (A), GM-CSF (B), Gro-alpha (C), IL-12p70 (D), IL-13 (E), IL-18 (F), IL-1 beta (G), IL-2 (H), IL-4 (I), IL-5 (J), IL-6 (K), IFN gamma (L), IP-10 (M), MCP-1 (N), MIP-1alpha (O), MIP-1 beta(P), RANTES (Q), SDF-1alpha (R) and TNF-alpha (S).
Supplementary Tables from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Authors: Sarker Debashis , Plummer Ruth , Meyer Tim , Sodergren Mikael H. , Basu Bristi , Chee Cheng Ean , Huang Kai-Wen , Palmer Daniel H. , Ma Yuk Ting , Evans T.R. Jeff , Spalding Duncan R.C. , Pai Madhava , Sharma Rohini , Pinato David J. , Spicer James , Hunter Sarah , Kwatra Vineet , Nicholls Joanna P. , Collin David , Nutbrown Robert , Glenny Helen , Fairbairn Sonia , Reebye Vikash , Voutila Jon , Dorman Stephanie , Andrikakou Pinelopi , Lloyd Peter , Felstead Steve , Vasara Jenni , Habib Robert , Wood Chris , Saetrom Pal , Huber Hans E. , Blakey David C. , Rossi John J. , Habib Nagy
Published: April 2023

Supplementary Table 1 CEBPA-51 PK parameters Supplementary Table 2 RECIST 1.1 response observed overall and per cohorts in HCC patients at cut-off (12 Sep 2018) presented as n (%)
Supplementary Legends from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Authors: Sarker Debashis , Plummer Ruth , Meyer Tim , Sodergren Mikael H. , Basu Bristi , Chee Cheng Ean , Huang Kai-Wen , Palmer Daniel H. , Ma Yuk Ting , Evans T.R. Jeff , Spalding Duncan R.C. , Pai Madhava , Sharma Rohini , Pinato David J. , Spicer James , Hunter Sarah , Kwatra Vineet , Nicholls Joanna P. , Collin David , Nutbrown Robert , Glenny Helen , Fairbairn Sonia , Reebye Vikash , Voutila Jon , Dorman Stephanie , Andrikakou Pinelopi , Lloyd Peter , Felstead Steve , Vasara Jenni , Habib Robert , Wood Chris , Saetrom Pal , Huber Hans E. , Blakey David C. , Rossi John J. , Habib Nagy
Published: April 2023

Supplementary Legends
Figure S1. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Authors: Merz Valeria , Zecchetto Camilla , Santoro Raffaela , Simionato Francesca , Sabbadini Fabio , Mangiameli Domenico , Piro Geny , Cavaliere Alessandro , Deiana Michela , Valenti Maria Teresa , Bazan Diana , Fedele Vita , Lonardi Sara , Melisi Davide
Published: April 2023

Immunohistochemical analysis. Serial paraffin sections from tumors excised from mice orthotopically inoculated with AsPC1 pancreatic cancer cells transduced with lentiviruses expressing shTAK1 (AsPC1shTAK1) or a scramble sequence as control (AsPC1ctrl) were stained with antibodies to CD68 or carboxylesterase-2 (CES2). We measured similarly minimal levels (less than 1 cell/field) of CD68+ cells with morphological features of tumor associated macrophages (TAM) and carboxylesterase-2 in tumor specimens excised from mice bearing shTAK1 AsPc1 tumors if compared with that in control tumors
Supplementary Figure 2 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Authors: Sarker Debashis , Plummer Ruth , Meyer Tim , Sodergren Mikael H. , Basu Bristi , Chee Cheng Ean , Huang Kai-Wen , Palmer Daniel H. , Ma Yuk Ting , Evans T.R. Jeff , Spalding Duncan R.C. , Pai Madhava , Sharma Rohini , Pinato David J. , Spicer James , Hunter Sarah , Kwatra Vineet , Nicholls Joanna P. , Collin David , Nutbrown Robert , Glenny Helen , Fairbairn Sonia , Reebye Vikash , Voutila Jon , Dorman Stephanie , Andrikakou Pinelopi , Lloyd Peter , Felstead Steve , Vasara Jenni , Habib Robert , Wood Chris , Saetrom Pal , Huber Hans E. , Blakey David C. , Rossi John J. , Habib Nagy
Published: April 2023

qPCR of CEBPA mRNA levels at days 2, 8 and 15 following treatment
Supplementary Table S4 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Authors: Autio Karen A. , Klebanoff Christopher A. , Schaer David , Kauh John Sae Wook , Slovin Susan F. , Adamow Matthew , Blinder Victoria S. , Brahmachary Manisha , Carlsen Michelle , Comen Elizabeth , Danila Daniel C. , Doman Thompson N. , Durack Jeremy C. , Fox Josef J. , Gluskin Jill S. , Hoffman David M. , Kang Suhyun , Kang Praneet , Landa Jonathan , McAndrew Philomena F. , Modi Shanu , Morris Michael J. , Novosiadly Ruslan , Rathkopf Dana E. , Sanford Rachel , Chapman Sonya C. , Tate Courtney M. , Yu Danni , Wong Phillip , McArthur Heather L.
Published: April 2023

Relationship between confounding factors and response (RECIST).
Figure S6 from Single-Cell–Derived Primary Rectal Carcinoma Cell Lines Reflect Intratumor Heterogeneity Associated with Treatment Response
Authors: Braun Rüdiger , Anthuber Lena , Hirsch Daniela , Wangsa Darawalee , Lack Justin , McNeil Nicole E. , Heselmeyer-Haddad Kerstin , Torres Irianna , Wangsa Danny , Brown Markus A. , Tubbs Anthony , Auslander Noam , Gertz E. Michael , Brauer Philip R. , Cam Margaret C. , Sackett Dan L. , Habermann Jens K. , Nussenzweig Andre , Ruppin Eytan , Zhang Zhongqiu , Rosenberg Daniel W. , Ried Thomas
Published: April 2023

SUPPLEMENTARY FIGURE S6: Volcano plots of gene expression analysis based on total RNA sequencing.
Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Authors: Autio Karen A. , Klebanoff Christopher A. , Schaer David , Kauh John Sae Wook , Slovin Susan F. , Adamow Matthew , Blinder Victoria S. , Brahmachary Manisha , Carlsen Michelle , Comen Elizabeth , Danila Daniel C. , Doman Thompson N. , Durack Jeremy C. , Fox Josef J. , Gluskin Jill S. , Hoffman David M. , Kang Suhyun , Kang Praneet , Landa Jonathan , McAndrew Philomena F. , Modi Shanu , Morris Michael J. , Novosiadly Ruslan , Rathkopf Dana E. , Sanford Rachel , Chapman Sonya C. , Tate Courtney M. , Yu Danni , Wong Phillip , McArthur Heather L.
Published: April 2023

Dose selection details, T cell activation/exhaustion flow assay and multiplex cytokine measurements.
Figure S5 from Single-Cell–Derived Primary Rectal Carcinoma Cell Lines Reflect Intratumor Heterogeneity Associated with Treatment Response
Authors: Braun Rüdiger , Anthuber Lena , Hirsch Daniela , Wangsa Darawalee , Lack Justin , McNeil Nicole E. , Heselmeyer-Haddad Kerstin , Torres Irianna , Wangsa Danny , Brown Markus A. , Tubbs Anthony , Auslander Noam , Gertz E. Michael , Brauer Philip R. , Cam Margaret C. , Sackett Dan L. , Habermann Jens K. , Nussenzweig Andre , Ruppin Eytan , Zhang Zhongqiu , Rosenberg Daniel W. , Ried Thomas
Published: April 2023

SUPPLEMENTARY FIGURE S5: Copy number of the PIK3CA locus based on WES data.
Figure S4 from Single-Cell–Derived Primary Rectal Carcinoma Cell Lines Reflect Intratumor Heterogeneity Associated with Treatment Response
Authors: Braun Rüdiger , Anthuber Lena , Hirsch Daniela , Wangsa Darawalee , Lack Justin , McNeil Nicole E. , Heselmeyer-Haddad Kerstin , Torres Irianna , Wangsa Danny , Brown Markus A. , Tubbs Anthony , Auslander Noam , Gertz E. Michael , Brauer Philip R. , Cam Margaret C. , Sackett Dan L. , Habermann Jens K. , Nussenzweig Andre , Ruppin Eytan , Zhang Zhongqiu , Rosenberg Daniel W. , Ried Thomas
Published: April 2023

SUPPLEMENTARY FIGURE S4: Phylogenetic analysis of SCDCLs based on miFISH.
Supplementary Material from A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy
Authors: Cai Jinhua , Zheng Junjiong , Shen Jun , Yuan Zhiyong , Xie Mingwei , Gao Miaomiao , Tan Hongqi , Liang Zhongguo , Rong Xiaoming , Li Yi , Li Honghong , Jiang Jingru , Zhao Huiying , Argyriou Andreas A. , Chua Melvin L.K. , Tang Yamei
Published: April 2023

This file named Supplementary Material includes supplementary methods, tables and figure legends.
Supplementary Data from Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study
Authors: Shi Yuankai , Cai Qiqing , Jiang Yu , Huang Gang , Bi Minghong , Wang Baocheng , Zhou Yuhong , Wang Guowen , Ying Hongyan , Tao Zhiwei , Shi Chunmei , Guo Qian , Gao Chao
Published: April 2023

supplementary data-tracking
Supplementary Table S2 from Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy
Authors: Klein Sebastian , Quaas Alexander , Noh Ka-Won , Cartolano Maria , Abedpour Nima , Mauch Cornelia , Quantius Jennifer , Reinhardt Hans Christian , Buettner Reinhard , Peifer Martin , Helbig Doris
Published: April 2023

mRNA expression data of PDS and SCC
Supplementary Table S1 from Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy
Authors: Klein Sebastian , Quaas Alexander , Noh Ka-Won , Cartolano Maria , Abedpour Nima , Mauch Cornelia , Quantius Jennifer , Reinhardt Hans Christian , Buettner Reinhard , Peifer Martin , Helbig Doris
Published: April 2023

Somatic Mutations in PDS
Figure S3 from Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy
Authors: Klein Sebastian , Quaas Alexander , Noh Ka-Won , Cartolano Maria , Abedpour Nima , Mauch Cornelia , Quantius Jennifer , Reinhardt Hans Christian , Buettner Reinhard , Peifer Martin , Helbig Doris
Published: April 2023

Figure S3
Supplementary Table S7 from Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer
Authors: Liu Bin , Ricarte Filho Julio , Mallisetty Apurva , Villani Cassandra , Kottorou Anastasia , Rodgers Kristen , Chen Chen , Ito Tomoaki , Holmes Kyla , Gastala Nicole , Valyi-Nagy Klara , David Odile , Gaba Ron C. , Ascoli Christian , Pasquinelli Mary , Feldman Lawrence E. , Massad Malek G. , Wang Tza-Huei , Jusue-Torres Ignacio , Benedetti Enrico , Winn Robert A. , Brock Malcolm V. , Herman James G. , Hulbert Alicia
Published: April 2023

Univariate and multivariate logistic regression analysis for risk of having NSCLC in late stages (n=53)
Figure S2 from Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy
Authors: Klein Sebastian , Quaas Alexander , Noh Ka-Won , Cartolano Maria , Abedpour Nima , Mauch Cornelia , Quantius Jennifer , Reinhardt Hans Christian , Buettner Reinhard , Peifer Martin , Helbig Doris
Published: April 2023

Figure S2
Supplementary Data from Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma
Authors: Bassaganyas Laia , Pinyol Roser , Esteban-Fabró Roger , Torrens Laura , Torrecilla Sara , Willoughby Catherine E. , Franch-Expósito Sebastià , Vila-Casadesús Maria , Salaverria Itziar , Montal Robert , Mazzaferro Vincenzo , Camps Jordi , Sia Daniela , Llovet Josep M.
Published: April 2023

Supplementary Table 3
Supplementary Table S2 from Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer
Authors: Liu Bin , Ricarte Filho Julio , Mallisetty Apurva , Villani Cassandra , Kottorou Anastasia , Rodgers Kristen , Chen Chen , Ito Tomoaki , Holmes Kyla , Gastala Nicole , Valyi-Nagy Klara , David Odile , Gaba Ron C. , Ascoli Christian , Pasquinelli Mary , Feldman Lawrence E. , Massad Malek G. , Wang Tza-Huei , Jusue-Torres Ignacio , Benedetti Enrico , Winn Robert A. , Brock Malcolm V. , Herman James G. , Hulbert Alicia
Published: April 2023

Univariate logistic regression analysis for risk of having NSCLC.
Figure S6 from Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
Authors: Giesen Danique , Broer Linda N. , Lub-de Hooge Marjolijn N. , Popova Irina , Howng Bruce , Nguyen Margaret , Vasiljeva Olga , de Vries Elisabeth G.E. , Pool Martin
Published: April 2023

In vivo kinetics of â�¸â�¹Zr-CX-072, â�¸â�¹Zr-PbCtrl and â�¸â�¹Zr-CX-072.
Figure S1 from Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
Authors: Giesen Danique , Broer Linda N. , Lub-de Hooge Marjolijn N. , Popova Irina , Howng Bruce , Nguyen Margaret , Vasiljeva Olga , de Vries Elisabeth G.E. , Pool Martin
Published: April 2023

CX-072, PbCtrl and CX-075 binding properties.
Supplementary Data from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Authors: Leuci Valeria , Donini Chiara , Grignani Giovanni , Rotolo Ramona , Mesiano Giulia , Fiorino Erika , Gammaitoni Loretta , D'Ambrosio Lorenzo , Merlini Alessandra , Landoni Elisa , Medico Enzo , Capellero Sonia , Giraudo Lidia , Cattaneo Giulia , Iaia Ilenia , Pignochino Ymera , Basiricò Marco , Vigna Elisa , Pisacane Alberto , Fagioli Franca , Ferrone Soldano , Aglietta Massimo , Dotti Gianpietro , Sangiolo Dario
Published: April 2023

Supplemental Figure Legends
Supplementary Figure S4 from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma
Authors: Dai Wei , Chung Dittman Lai-Shun , Chow Larry Ka-Yue , Yu Valen Zhuoyou , Lei Lisa Chan , Leong Merrin Man-Long , Chan Candy King-Chi , Ko Josephine Mun-Yee , Lung Maria Li
Published: April 2023

Figure S4: Kaplan-Meier plot of progression-free survival (PFS) in the HK-1 cohort. The patients were categorized into two groups. One group has both detectable signature 3 and MMR signature and the remaining cases are in the other group. The hazard ratio was estimated by the univariate Cox analysis.
Supplemental Figure 2 from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Authors: Leuci Valeria , Donini Chiara , Grignani Giovanni , Rotolo Ramona , Mesiano Giulia , Fiorino Erika , Gammaitoni Loretta , D'Ambrosio Lorenzo , Merlini Alessandra , Landoni Elisa , Medico Enzo , Capellero Sonia , Giraudo Lidia , Cattaneo Giulia , Iaia Ilenia , Pignochino Ymera , Basiricò Marco , Vigna Elisa , Pisacane Alberto , Fagioli Franca , Ferrone Soldano , Aglietta Massimo , Dotti Gianpietro , Sangiolo Dario
Published: April 2023

CSPG4-CAR.CIK in vitro cytolytic activity against 12 distinct STS histotypes
Suppl. Video 6 from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Authors: Leuci Valeria , Donini Chiara , Grignani Giovanni , Rotolo Ramona , Mesiano Giulia , Fiorino Erika , Gammaitoni Loretta , D'Ambrosio Lorenzo , Merlini Alessandra , Landoni Elisa , Medico Enzo , Capellero Sonia , Giraudo Lidia , Cattaneo Giulia , Iaia Ilenia , Pignochino Ymera , Basiricò Marco , Vigna Elisa , Pisacane Alberto , Fagioli Franca , Ferrone Soldano , Aglietta Massimo , Dotti Gianpietro , Sangiolo Dario
Published: April 2023

NTD.CIK vs S5 - 3D-RECONSTRUCTION
Table S1 from A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer
Authors: Prat Aleix , Tsai Yi-Hsuan , Pascual Tomás , Paré Laia , Adamo Barbara , Vidal Maria , Brasó-Maristany Fara , Galván Patricia , Brase Jan Christoph , Rodrik-Outmezguine Vanessa , Johnston Stephen , Ciruelos Eva , Parker Joel S.
Published: April 2023

Clinical-pathological and genomic variable (n = 21) used to calculate the PAM50MET model. PAM50MET, final model.
Suppl. Video 4 from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Authors: Leuci Valeria , Donini Chiara , Grignani Giovanni , Rotolo Ramona , Mesiano Giulia , Fiorino Erika , Gammaitoni Loretta , D'Ambrosio Lorenzo , Merlini Alessandra , Landoni Elisa , Medico Enzo , Capellero Sonia , Giraudo Lidia , Cattaneo Giulia , Iaia Ilenia , Pignochino Ymera , Basiricò Marco , Vigna Elisa , Pisacane Alberto , Fagioli Franca , Ferrone Soldano , Aglietta Massimo , Dotti Gianpietro , Sangiolo Dario
Published: April 2023

NTD.CIK vs S5 - INFILTRATION
Supplementary Table S3 from Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Authors: Facchinetti Francesco , Hollebecque Antoine , Bahleda Rastislav , Loriot Yohann , Olaussen Ken A. , Massard Christophe , Friboulet Luc
Published: April 2023

Ongoing trials evaluating selective FGFR inhibitors in tumors harboring FGFR alterations.
Supplementary Table S1 from Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Authors: Facchinetti Francesco , Hollebecque Antoine , Bahleda Rastislav , Loriot Yohann , Olaussen Ken A. , Massard Christophe , Friboulet Luc
Published: April 2023

Phase I trials of selective FGFR inhibitors encompassing a dose-escalation phase and lacking a precise histologic/molecular selection (with the exception of Debio 1347)
Figure S5 from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Authors: Crosby Erika J. , Acharya Chaitanya R. , Haddad Anthony-Fayez , Rabiola Christopher A. , Lei Gangjun , Wei Jun-Ping , Yang Xiao-Yi , Wang Tao , Liu Cong-Xiao , Wagner Kay U. , Muller William J. , Chodosh Lewis A. , Broadwater Gloria , Hyslop Terry , Shepherd Jonathan H. , Hollern Daniel P. , He Xiaping , Perou Charles M. , Chai Shengjie , Ashby Benjamin K. , Vincent Benjamin G. , Snyder Joshua C. , Force Jeremy , Morse Michael A. , Lyerly Herbert K. , Hartman Zachary C.
Published: April 2023

Supplementary Figure 5